Arrhythmia/EP
Apixaban cuts stroke risk in all types of AF, says ARISTOTLE
2 COMMENT S - May 16, 2012 09:30 EDT
The trial also had something to say about the degree of stroke risk according to type of atrial fibrillation—that is, whether paroxysmal or permanent/persistent.

Boston, MA - The primary conclusion of the ARISTOTLE trial, that the direct factor Xa inhibitor apixaban (Eliquis, Pfizer/Bristol-Myers Squibb) is better than warfarin at preventing stroke or systemic embolism in patients with atrial fibrillation (AF), applies regardless of whether AF is paroxysmal or either permanent or persistent [1].

That's from a prospectively planned secondary analysis of the trial that also shows that apixaban lowers the risk of bleeding complications better than the older anticoagulant in both types of AF. It was presented here last week at the Heart Rhythm Society 2012 Scientific Sessions by Dr Sana Al-Khatib (Duke Clinical Research Institute, Duke University, Durham, NC). Entry into ARISTOTLE called for AF plus at least one other stroke/embolism risk factor.
Read full article »

Heart failure
ARISTOTLE "heart-failure substudy" sees apixaban stroke protection regardless of HF, LV function
May 21, 2012 12:00 EDT

Heart failure
SHIFT: Falling HR, not beta blockade, key to ivabradine success in HF
May 21, 2012 10:30 EDT

Heart failure
2012 European HF guidelines cover new ground: TAVI, ivabradine make debuts
May 21, 2012 09:15 EDT

Arrhythmia/EP
"Are we downsizing in vain?" Lead size, venous occlusion found unrelated
May 18, 2012 12:30 EDT

Brain/Kidney/Peripheral
Strokes down in new TAVI analyses
May 18, 2012 09:00 EDT

Arrhythmia/EP
Azithromycin may up chance of sudden cardiac death
May 16, 2012 17:00 EDT

From the blogsView all »
Trials and Fibrillations with
Dr John Mandrola
Mandrola
Is dabigatran an appropriate periprocedural anticoagulant? Review of recent data and HRS 2012 abstracts
May 17, 2012 06:52 EDT
Editorial programs
Debate and dialogue between top cardiovascular specialists, produced by
theheart.org's editorial team
View all »
The creative destruction of medicine with Dr Eric Topol
The creative destruction of medicine with Dr Eric Topol
Apr 24, 2012 13:30 EDT
ACC 2012 research highlights: A slideshow presentation
ACC 2012 research highlights: A slideshow presentation
Mar 29, 2012 11:19 EDT
The ACC 2012 Roundup: PARTNER A, TRA 2°P, STAMPEDE, ROMICAT II, and ACRIN-PA
The ACC 2012 Roundup: PARTNER A, TRA 2°P, STAMPEDE, ROMICAT II, and ACRIN-PA
1 COMMENT - Mar 28, 2012 11:18 EDT
View all »Collections
heartwire collections groups our most compelling cardiology news coverage and editorial content by popular themes. Find everything on a single topic, in one place, with one click.
Antiplatelet up-and-comers
The quest for ever-more effective drugs to decrease platelet aggregation and reduce the...
Aspirin and primary prevention
Long considered an essential agent for primary cardiovascular disease prevention...
Dabigatran: A chronology
The presentation of the RE-LY results at the 2009 ESC meeting, showing that dabigatran...
MRIs and implantable device safety
Magnetic resonance imaging tests are increasingly being used for diagnosing forms of...
Drugs, money, and glory: Is cancer beating cardiovascular disease?
Heart disease still tops the charts as the number-one killer in most developed...
ECG of the month (view all)
What is the primary ECG disorder shown in this tracing?
What is the primary ECG disorder shown in this tracing?
May 1, 2012 08:34 EDT
What is the clinical significance of electrical alternans in this tracing?
What is the clinical significance of electrical alternans in this tracing?
Apr 12, 2012 10:02 EDT
Resource Center (view all)

What's New